The reiteration of an Equal-Weight rating and maintenance of a $4 price target by Stephens & Co. suggests a neutral short-term impact on OncoCyte's stock price. The analyst's view indicates no significant change in the company's valuation or outlook, which is why the score is neutral. The high relevance is due to the direct mention of OncoCyte and its stock symbol OCX. The importance is significant as analyst ratings can influence market perception and investor decisions. The confidence level is high due to the clear stance of the analyst firm on OncoCyte's stock.